Daniel J. Wallace

42.4k citations
319 papers · 17.6k · 10 hit papers · h-index 65

Impact in

  • Rheumatology top 0.01%
    • Systemic Lupus Erythematosus Research
    • Rheumatoid Arthritis Research and Therapies
  • Immunology top 0.1%
    • T-cell and B-cell Immunology
    • Atherosclerosis and Cardiovascular Diseases
    • Immune Cell Function and Interaction

Papers in

    • Systemic Lupus Erythematosus Research 183
    • Rheumatoid Arthritis Research and Therapies 16
    • T-cell and B-cell Immunology 20

Daniel J. Wallace

301 papers receiving 16.6k citations

Daniel J. Wallace's Hit Papers

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) 2023 · 91 citations
910+12+25Years since publication4008001.2k

Peers

Daniel J. Wallace
Comparison fields: 5 of 174
  • Rheumatology 11.4k
  • Immunology 6.8k
  • Radiology, Nuclear Medicine and Imaging 3.7k
  • Nephrology 1.1k
  • Hematology 935
Replace Caroline Gordon with:
Caroline Gordon United Kingdom
Andrea Doria Italy
Michelle Petri United States
Ronald van Vollenhoven Sweden
John D. Reveille United States
Eric L. Matteson United States
Graciela S. Alarcón United States
Dennis J. McShane United States
Guido Valesini Italy
Daniel E. Fürst United States
Daniel J. Wallace relative to Caroline Gordon United Kingdom Caroline Gordon's profile →
Citations per field
00.5×1.5×
Caroline Gordon · 1×
Citations per year

Countries citing papers authored by Daniel J. Wallace

Since Specialization
Citations

This map shows the geographic impact of Daniel J. Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Wallace more than expected).

Fields of papers citing papers by Daniel J. Wallace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Wallace. The network helps show where Daniel J. Wallace may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel J. Wallace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel J. Wallace Line = papers co-authored together Daniel J. Wallace links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 319 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Hit paper breakdown →
20111236
2
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Hit paper breakdown →
20091043
3
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Hit paper breakdown →
2005838
4
Dubois' Lupus Erythematosus
Hit paper breakdown →
1988586
5
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Hit paper breakdown →
2005519
6
A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
Hit paper breakdown →
2003492
7 1991474
8
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
Hit paper breakdown →
2009439
9
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Hit paper breakdown →
2018376
10
Novel evidence‐based systemic lupus erythematosus responder index
Hit paper breakdown →
2009359
11 2006343
12 2010295
13 2001267
14 2013265
15 2007253
16 1981234
17 1997223
18 2006209
19 2013208
20 1981191

About Daniel J. Wallace

Daniel J. Wallace is a scholar working on Rheumatology, Immunology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Psychiatry and Mental health, having authored 319 papers that have together received 17.6k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (183 papers), Monoclonal and Polyclonal Antibodies Research (28 papers), T-cell and B-cell Immunology (20 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (18 papers), Rheumatoid Arthritis Research and Therapies (16 papers), Systemic Sclerosis and Related Diseases (12 papers), Salivary Gland Disorders and Functions (10 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). The work is most often cited by research in Rheumatology (11.4k citations), Immunology (6.8k citations), Radiology, Nuclear Medicine and Imaging (3.7k citations), Nephrology (1.1k citations) and Hematology (935 citations). Daniel J. Wallace has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Michael H. Weisman, Joan T. Merrill, Michelle Petri, Richard Furie, Ellen M. Ginzler, James R. Klinenberg, Mariana Linker‐Israeli, Kenneth Kalunian, David Isenberg and William Stohl. Their work appears in journals such as Lupus, Annals of the Rheumatic Diseases, Seminars in Arthritis and Rheumatism, Arthritis & Rheumatology and Lupus Science & Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact